After potential target screening, six DCM-associated targets of triptolide were identified (STAT3, VEGFA, FOS, TNF, TP53, and TGFB1), suggesting that these targets may play key roles in the treatment of DCM by triptolide. This evidence concerns the gene TGFB1 and familial dilated cardiomyopathy.